{"name":"Passage Bio, Inc.","slug":"passage","ticker":"PASG","exchange":"NASDAQ","domain":"passagebio.com","description":"Passage Bio, Inc. is a biotechnology company focused on developing gene therapies for rare genetic diseases. The company's pipeline includes several promising candidates, including PBGMK01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. With a strong focus on gene editing and gene therapy, Passage Bio aims to revolutionize the treatment of rare genetic diseases. As a relatively new player in the gene therapy space, the company is poised for growth and expansion.","hq":"Philadelphia, PA","founded":0,"employees":"","ceo":"Gary Romano","sector":"Biotech — Gene Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":23276000,"netIncome":-45522000,"cash":46303000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"earnings","headline":"Passage Bio Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Passage Bio reported its fourth quarter and full year 2022 financial results, with a net loss of $44.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-06-09","type":"deal","headline":"Passage Bio Announces Collaboration with the Michael J. Fox Foundation for Parkinson's Research","summary":"Passage Bio announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to develop a gene therapy for Parkinson's disease.","drugName":"","sentiment":"positive"},{"date":"2022-03-14","type":"regulatory","headline":"Passage Bio Announces FDA Clearance of IND for PBGMK01 for GM1 Gangliosidosis","summary":"Passage Bio announced that the FDA had cleared the Investigational New Drug (IND) application for PBGMK01, a gene therapy for GM1 gangliosidosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM0p0NzkwcUxacVBNUm1BQktfa2hIaEtGSWd0bFkzV3lSNUhyREdhdC1UVmR3SEMyUWxLTmpJWDgwYW1pODBCOTV1bWlZX3BBY2Vubzh3WU1sZXl5UXpJRWJEa0dBX3V4U0tESDNkWFpqcmVpcDc1TkdscDZLWGpWWjN6dVVnLXUxRmM2U1cwSFdhMFNWX1lLcGk0SFlXcUppREpVLXhnaVBHNkVoWW1qUTB4cExQQ2hv?oc=5","date":"2026-04-01","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbHpJcXBvaDdfN0FSNkNidFFKM1VYR21tOGJqNUZtQzNmMVlEQTBWRXhadlg3T2JZUXZMVldENExXaE1FdlNQdnJHZGZCdWd4b1RQUkN3STU1bjB2bm9ER2w0bzhaV2E2YUJqT2JCRXoyNGw4NWRYSFB2SDM5NHFWVVBlRDJpTGZKUkJseFBTa0FDNjBuUTYtRE53dWRYblBxenkxMmVZR1RaVW8wLWdfTTFFRTN5c1pFeTlEVm1SMlY?oc=5","date":"2026-04-01","type":"pipeline","source":"AD HOC NEWS","summary":"Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena - AD HOC NEWS","headline":"Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOS0Y5c0EzWkdxeDV5a28zOFpCVkpKSEg2NmlZR1hVUGVXR3BjZmh1RHo2U0NFT2p2NTctclpIdFBJSWNUa2otNEkzMV8wTWhHSFQ5M0tBN2RreU1aajg4Y25NQnRXSmdrakttYjFOcTJVVDMtTDZiMVN1LUozV3k0NkFwVUg3UE9zamdlMGc4dmdfd2I0c1BmekVoenM2em1MTWthVllvS1JNMFlGZkVPWjctX0swVHA2aUlxQUJvbEZFQ3hqUFE?oc=5","date":"2026-03-29","type":"pipeline","source":"AD HOC NEWS","summary":"Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo - AD HOC NEWS","headline":"Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQYTBHa1k5ZG03UTA3VmM2bUJPbzd5TGVCM2lueDUzRUdCT0FNcGQtNU05UVl2el9JenFISUVyTGM4LWxhUWU3aTN3RzdCRlBzT3h3MXpJb1VUVGQwbGZkOEd2a19VR2VpSURnWVZWM3dCX01JdkFLUGk1UTdLNlFKX092QzBQUEFFQll0eGV4b2tnVEJSZ183amFNb1BGdU12TW92dVF6a2VtUVFDSndpc0lST3owN2k4LWlLQVVmYw?oc=5","date":"2026-03-15","type":"pipeline","source":"AD HOC NEWS","summary":"Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS","headline":"Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNME53YzdMT2FLdFRnTmVQLXJidVM1ckQtbmwxa2ktVDVfZ1pSLVRNeThkcTQzdG5qM3ZKWWtYNkhXLUtaU3dzVnZEb1hfZDN6aW4tRnZxWGdocjNwZk1GTTdjR1U3cHRRX094TkVWc1FhSzZRbmpoNnBZQmo4T2hDWHNrejFyb1dwVDB0N1Vqa3hTSjdvdGRnZGNfWjlKTjRMajladmg2c2RXUUY0U3dPOGFaSnBPWHlwaFE?oc=5","date":"2026-03-03","type":"pipeline","source":"Stock Titan","summary":"Passage Bio enrolls FTD patients, advances Huntington’s program - Stock Titan","headline":"Passage Bio enrolls FTD patients, advances Huntington’s program","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOaDhsdFdwVGdGZmtfcFo0NVdaeERtcWdWSEx0bmdNRV9aUUsyZzgwSEhTOWlQdU5scWFXMzAtN0tGSDhySU1KOEYxV0MxdVg0NUdBTWN1bms0QVVlMDhmRE1YNllUU2dyU0NadHhyc19ZNy1hWm90ekFwZ3VRZFZUOTlYUWZIVFFETFZFT0tKRHI4TElwdVJoZ0txVDZxQjM0OVJKNFI4bV9mM1JfWWwwY0NKRWlPVUpQX0hZYjZITncxRmlfZnFJUnFGdGdBUVp2Y0drZkN2dVdpbGZMZmlra0lHQnU?oc=5","date":"2024-12-03","type":"pipeline","source":"Business Wire","summary":"Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology - Business Wire","headline":"Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE4zalNwUno2bWx0RS1YbG4yVVFxN2pQZElqUTltTGFFa1huZERDcWIxY0NUci1YdHRCZjh3VVRtYlRXdDlXWm1NSkJ1WFE2UmF2ZlE?oc=5","date":"2020-11-20","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Passage Bio, Inc. (PASG) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Passage Bio, Inc. (PASG) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE0ySU1pYkI2OF9INDNHVFFxRHZuMmszRGJad3lXZUNRaDluM2FZME5JZFN1Mi0taFpILUNGSWdSSjUwR2VhczNOUUNfWUNvLWZWT1YwZ0NfM19Edw?oc=5","date":"2020-03-04","type":"pipeline","source":"MarketBeat","summary":"Passage Bio (PASG) Stock Price, News & Analysis - MarketBeat","headline":"Passage Bio (PASG) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Voyager Therapeutics"],"therapeuticFocus":["Gene Therapy","Rare Genetic Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":23276000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-45522000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":46303000,"cashHistory":[],"totalAssets":62281000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}